Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 19
2003 11
2004 16
2005 19
2006 19
2007 35
2008 21
2009 15
2010 14
2011 28
2012 29
2013 18
2014 21
2015 22
2016 23
2017 26
2018 27
2019 38
2020 27
Text availability
Article attribute
Article type
Publication date

Search Results

380 results
Results by year
Filters applied: . Clear all
Page 1
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Antonia SJ, et al. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8. N Engl J Med. 2017. PMID: 28885881 Free article. Clinical Trial.
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Antonia SJ, et al. N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280658 Clinical Trial.
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Mok TS, et al. N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6. N Engl J Med. 2017. PMID: 27959700 Free PMC article. Clinical Trial.
Managing Lung Cancer with Comorbid Interstitial Pneumonia.
Ichihara E, Miyahara N, Maeda Y, Kiura K. Ichihara E, et al. Among authors: kiura k. Intern Med. 2020 Jan 15;59(2):163-167. doi: 10.2169/internalmedicine.3481-19. Epub 2019 Sep 18. Intern Med. 2020. PMID: 31534086 Free PMC article. Review.
Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia.
Ogura T, Takigawa N, Tomii K, Kishi K, Inoue Y, Ichihara E, Homma S, Takahashi K, Akamatsu H, Ikeda S, Inase N, Iwasawa T, Ohe Y, Ohta H, Onishi H, Okamoto I, Ogawa K, Kasahara K, Karata H, Kishimoto T, Kitamura Y, Gemma A, Kenmotsu H, Sakashita H, Sakamoto S, Sekine K, Takiguchi Y, Tada Y, Toyooka S, Nakayama Y, Nishioka Y, Hagiwara K, Hanibuchi M, Fukuoka J, Minegishi Y, Yanagihara T, Yamamoto N, Yamamoto H, Gaga M, Fong KM, Powell CA, Kiura K; DLD/TO Assemblies of JRS. Ogura T, et al. Among authors: kiura k. Respir Investig. 2019 Nov;57(6):512-533. doi: 10.1016/j.resinv.2019.06.001. Epub 2019 Aug 1. Respir Investig. 2019. PMID: 31377122 Review.
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E. Shaw AT, et al. Among authors: kiura k. Lancet Oncol. 2017 Jul;18(7):874-886. doi: 10.1016/S1470-2045(17)30339-X. Epub 2017 Jun 9. Lancet Oncol. 2017. PMID: 28602779 Clinical Trial.
A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.
Hotta K, Aoe K, Kozuki T, Ohashi K, Ninomiya K, Ichihara E, Kubo T, Ninomiya T, Chikamori K, Harada D, Nogami N, Hirata T, Hinotsu S, Toyooka S, Kiura K. Hotta K, et al. Among authors: kiura k. J Thorac Oncol. 2018 Feb;13(2):273-279. doi: 10.1016/j.jtho.2017.10.032. Epub 2017 Dec 5. J Thorac Oncol. 2018. PMID: 29313813 Free article. Clinical Trial.
The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
Watanabe H, Kubo T, Ninomiya K, Kudo K, Minami D, Murakami E, Ochi N, Ninomiya T, Harada D, Yasugi M, Ichihara E, Ohashi K, Fujiwara K, Hotta K, Tabata M, Maeda Y, Kiura K. Watanabe H, et al. Among authors: kiura k. Jpn J Clin Oncol. 2019 Aug 1;49(8):762-765. doi: 10.1093/jjco/hyz066. Jpn J Clin Oncol. 2019. PMID: 31090906
Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
Hirashima T, Satouchi M, Hida T, Nishio M, Kato T, Sakai H, Imamura F, Kiura K, Okamoto I, Kasahara K, Uchida H, Vowler SL, Mitsudomi T. Hirashima T, et al. Among authors: kiura k. Cancer Sci. 2019 Sep;110(9):2884-2893. doi: 10.1111/cas.14120. Epub 2019 Aug 1. Cancer Sci. 2019. PMID: 31265163 Free PMC article. Clinical Trial.
The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer.
Ichihara E, Harada D, Inoue K, Sato K, Hosokawa S, Kishino D, Watanabe K, Ochi N, Oda N, Hara N, Hotta K, Maeda Y, Kiura K. Ichihara E, et al. Among authors: kiura k. Lung Cancer. 2020 Jan;139:140-145. doi: 10.1016/j.lungcan.2019.11.011. Epub 2019 Nov 18. Lung Cancer. 2020. PMID: 31786476
380 results
Jump to page
Feedback